Search

Your search keyword '"Baz, Rachid"' showing total 1,022 results
Start Over Author "Baz, Rachid"
1,022 results on '"Baz, Rachid"'

1. Immune effector cell-associated enterocolitis following chimeric antigen receptor T-cell therapy in multiple myeloma

Author

Fortuna, Gliceida Galarza, Banerjee, Rahul, Savid-Frontera, Constanza, Song, Jinming, Morán-Segura, Carlos M., Nguyen, Jonathan V., Lekakis, Lazaros, Fernandez-Pol, Sebastian, Samraj, Annie N., Naresh, Kikkeri N., Vazquez-Martinez, Mariola, Baz, Rachid C., Spiegel, Jay Y., Mikkilineni, Lekha, Gubatan, John M., Sidana, Surbhi, de Menezes Silva Corraes, Andre, Kalariya, Nilesh M., Patel, Krina K., Shim, Kevin G., Fonseca, Rafael, Ferreri, Christopher, Voorhees, Peter M., Richard, Shambavi, Valdes, Cesar Rodriguez, Sireesha Asoori, Wolf, Jeffrey L., Cowan, Andrew J., Sborov, Douglas W., Locke, Frederick L., Lin, Yi, Wang, Yinghong, and Hansen, Doris K.

Published
2024
Full Text
View/download PDF

2. Abstract 4114505: Cardiovascular Adverse Events After Anti-BCMA CAR-T (Ide-Cel and Cilta-Cel) for Relapsed/ Refractory Multiple Myeloma

Author

Palfi, Stefanie, Koelmeyer, Himara, Alsina, Melissa, Baz, Rachid, Blue, Brandon, Corallo, Salvatore, De Avila, Gabriel, Freeman, Ciara, Grajales-Cruz, Ariel, Harvey, Kristy, Liu, Hien, Nishihori, Taiga, Oliveira, Guilherme, Oswald, Laura, Castaneda Puglianini, Omar, Shain, Kenneth, Wettenstein, Zachary, Jain, Michael, Locke, Frederick, Alomar, Mohammed, Hansen, Doris, and Lee, Dae Hyun

Published
2024
Full Text
View/download PDF

3. Ide-cel vs standard regimens in triple-class–exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses

Author

Ailawadhi, Sikander, Arnulf, Bertrand, Patel, Krina, Cavo, Michele, Nooka, Ajay K., Manier, Salomon, Callander, Natalie, Costa, Luciano J., Vij, Ravi, Bahlis, Nizar J., Moreau, Philippe, Solomon, Scott, Abrahamsen, Ingerid Weum, Baz, Rachid, Broijl, Annemiek, Chen, Christine, Jagannath, Sundar, Raje, Noopur, Scheid, Christof, Delforge, Michel, Benjamin, Reuben, Pabst, Thomas, Iida, Shinsuke, Berdeja, Jesús, Giralt, Sergio, Truppel-Hartmann, Anna, Chen, Yanping, Zhong, Xiaobo, Wu, Fan, Piasecki, Julia, Eliason, Laurie, Dhanda, Devender, Felten, Jasper, Caia, Andrea, Cook, Mark, Popa McKiver, Mihaela, and Rodríguez-Otero, Paula

Published
2024
Full Text
View/download PDF

4. Safety and efficacy of anti-BCMA CAR-T cell therapy in older adults with multiple myeloma: A systematic review and meta-analysis

Author

Akhtar, Othman Salim, Sheeba, Ba Aqeel, Azad, Farhan, Alessi, Lauren, Hansen, Doris, Alsina, Melissa, Baz, Rachid, Shain, Kenneth, Grajales Cruz, Ariel, Castaneda Puglianini, Omar, Liu, Hien, Blue, Brandon, Nishihori, Taiga, Al Jumayli, Mohammed, Extermann, Martine, Locke, Frederick L., Mhaskar, Rahul, and Freeman, Ciara Louise

Published
2024
Full Text
View/download PDF

5. Cardiac events after standard of care idecabtagene vicleucel for relapsed and refractory multiple myeloma

Author

Lee, Dae Hyun, Kumar, Abhishek, Mohammed, Turab, Peres, Lauren C., Alsina, Melissa, Bachmeier, Christina, Blue, Brandon J., Brayer, Jason, Chandrasekhar, Sanjay, Grajales Cruz, Ariel, De Avila, Gabe, Elmariah, Hany, Faramand, Rawan, Freeman, Ciara, Jain, Michael, Khadka, Sushmita, Khimani, Farhad, Liu, Hien, Nishihori, Taiga, Oswald, Laura B., Castaneda Puglianini, Omar A., Shain, Kenneth H., Smith, Eric, Baz, Rachid C., Locke, Frederick L., Oliveira, Guilherme H., Alomar, Mohammed, and Hansen, Doris K.

Published
2023
Full Text
View/download PDF

6. Integrated safety profile of selinexor in multiple myeloma: experience from 437 patients enrolled in clinical trials.

Author

Gavriatopoulou, Maria, Chari, Ajai, Chen, Christine, Bahlis, Nizar, Vogl, Dan, Jakubowiak, Andrzej, Dingli, David, Cornell, Robert, Hofmeister, Craig, Siegel, David, Berdeja, Jesus, Reece, Donna, White, Darrell, Lentzsch, Suzanne, Gasparetto, Cristina, Huff, Carol, Jagannath, Sundar, Baz, Rachid, Nooka, Ajay, Richter, Joshua, Abonour, Rafat, Parker, Terri, Yee, Andrew, Moreau, Philippe, Lonial, Sagar, Tuchman, Sascha, Weisel, Katja, Mohty, Mohamad, Choquet, Sylvain, Unger, T, Li, Kai, Chai, Yi, Li, Lingling, Shah, Jatin, Shacham, Sharon, Kauffman, Michael, and Dimopoulos, Meletios

Subjects
Aged, Antineoplastic Agents, Appetite, Clinical Trials as Topic, Diarrhea, Fatigue, Female, Humans, Hydrazines, Hyponatremia, Male, Middle Aged, Multiple Myeloma, Nausea, Thrombocytopenia, Triazoles
Abstract

Selinexor is an oral, small molecule inhibitor of the nuclear export protein exportin 1 with demonstrated activity in hematologic and solid malignancies. Side effects associated with selinexor include nausea, vomiting, fatigue, diarrhea, decreased appetite, weight loss, thrombocytopenia, neutropenia, and hyponatremia. We reviewed 437 patients with multiple myeloma treated with selinexor and assessed the kinetics of adverse events and impact of supportive care measures. Selinexor reduced both platelets and neutrophils over the first cycle of treatment and reached a nadir between 28 and 42 days. Platelet transfusions and thrombopoietin receptor agonists were effective at treating thrombocytopenia, and granulocyte colony stimulating factors were effective at resolving neutropenia. The onset of gastrointestinal side effects (nausea, vomiting, and diarrhea) was most common during the first 1-2 weeks of treatment. Nausea could be mitigated with 5-HT3 antagonists and either neurokinin 1 receptor antagonists, olanzapine, or cannbainoids. Loperamide and bismuth subsalicylate ameliorated diarrhea. The primary constitutional side effects of fatigue and decreased appetite could be managed with methylphenidate, megestrol, cannabinoids or olanzapine, respectively. Hyponatremia was highly responsive to sodium replacement. Selinexor has well-established adverse effects that mainly occur within the first 8 weeks of treatment, are reversible, and respond to supportive care.

Published
2020

7. Early cytopenias and infections after standard of care idecabtagene vicleucel in relapsed or refractory multiple myeloma

Author

Logue, Jennifer M., Peres, Lauren C., Hashmi, Hamza, Colin-Leitzinger, Christelle M., Shrewsbury, Alexandria M., Hosoya, Hitomi, Gonzalez, Rebecca M., Copponex, Christina, Kottra, Krista H., Hovanky, Vanna, Sahaf, Bita, Patil, Sunita, Lazaryan, Aleksandr, Jain, Michael D., Baluch, Aliyah, Klinkova, Olga V., Bejanyan, Nelli, Faramand, Rawan G., Elmariah, Hany, Khimani, Farhad, Davila, Marco L., Mishra, Asmita, Blue, Brandon J., Grajales-Cruz, Ariel F., Castaneda Puglianini, Omar A., Liu, Hien D., Nishihori, Taiga, Freeman, Ciara L., Brayer, Jason B., Shain, Kenneth H., Baz, Rachid C., Locke, Frederick L., Alsina, Melissa, Sidana, Surbhi, and Hansen, Doris K.

Published
2022
Full Text
View/download PDF

8. Absolute Lymphocyte Count and Outcomes of Multiple Myeloma Patients Treated with Idecabtagene Vicleucel: The US Myeloma Immunotherapy Consortium Real- World Experience

Author

Khouri, Jack, Dima, Danai, Li, Hong, Hansen, Doris, Sidana, Surbhi, Shune, Leyla, Anwer, Faiz, Sborov, Douglas, Wagner, Charlotte, Kocoglu, Mehmet H., Atrash, Shebli, Voorhees, Peter, Peres, Lauren, Hovanky, Vanna, Simmons, Gary, Williams, Louis, Raza, Shahzad, Afrough, Aimaz, Anderson, Larry D., Jr, Ferreri, Christopher, Hashmi, Hamza, Davis, James, McGuirk, Joseph, Goldsmith, Scott, Borogovac, Azra, Lin, Yi, Midha, Shonali, Nadeem, Omar, Locke, Frederick L., Baz, Rachid, Hamilton, Betty, Alsina, Melissa, Sauter, Craig, Patel, Krina, and Kaur, Gurbakhash

Published
2024
Full Text
View/download PDF

10. Racial and ethnic differences in clonal hematopoiesis, tumor markers, and outcomes of patients with multiple myeloma

Author

Peres, Lauren C., Colin-Leitzinger, Christelle M., Teng, Mingxiang, Dutil, Julie, Alugubelli, Raghunandan R., DeAvila, Gabriel, Teer, Jamie K., Du, Dongliang, Mo, Qianxing, Siegel, Erin M., Hampton, Oliver A., Alsina, Melissa, Brayer, Jason, Blue, Brandon, Baz, Rachid, Silva, Ariosto S., Nishihori, Taiga, Shain, Kenneth H., and Gillis, Nancy

Published
2022
Full Text
View/download PDF

13. Twice-weekly ixazomib in combination with lenalidomide-dexamethasone in patients with newly diagnosed multiple myeloma.

Author

Richardson, Paul, Hofmeister, Craig, Rosenbaum, Cara, Htut, Myo, Vesole, David, Berdeja, Jesus, Liedtke, Michaela, Chari, Ajai, Smith, Stephen, Lebovic, Daniel, Raje, Noopur, Byrne, Catriona, Liao, Eileen, Gupta, Neeraj, Bacco, Alessandra, Estevam, Jose, Berg, Deborah, and Baz, Rachid

Subjects
ixazomib, multiple myeloma, newly diagnosed, oral, twice-weekly, Administration, Oral, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Boron Compounds, Dexamethasone, Disease-Free Survival, Dose-Response Relationship, Drug, Drug Administration Schedule, Female, Glycine, Humans, Lenalidomide, Male, Middle Aged, Multiple Myeloma, Treatment Outcome
Abstract

Weekly ixazomib with lenalidomide-dexamethasone (Rd) is feasible and has shown activity in newly diagnosed multiple myeloma (NDMM) patients. This phase 1/2 study (NCT01383928) evaluated the recommended phase 2 dose (RP2D), pharmacokinetics, safety and efficacy of twice-weekly ixazomib plus Rd in NDMM; 64 patients were enrolled across both phases. Patients received twice-weekly oral ixazomib 3·0 or 3·7 mg plus lenalidomide 25 mg and dexamethasone 20 mg (10 mg in cycles 9-16) for up to sixteen 21-day cycles, followed by maintenance with twice-weekly ixazomib alone. No dose-limiting toxicities were reported in cycle 1; the RP2D was 3·0 mg based on overall tolerability across multiple cycles. In 62 evaluable patients, the confirmed overall response rate was 94% (68% ≥very good partial response; 24% complete response). Median progression-free survival was 24·9 months. Responses (median duration 36·9 months for patients receiving the RP2D) deepened during treatment. Grade 3 drug-related adverse events (AEs) occurred in 64% of patients, including: rash, 13%; peripheral neuropathy, 8%; hyperglycaemia, 8%. There were no grade 4 drug-related AEs. Thirteen patients discontinued due to AEs. Twice-weekly ixazomib-Rd offers substantial activity with promising long-term outcomes in NDMM patients but may be associated with greater toxicity compared with weekly ixazomib-Rd in this setting.

Published
2018

14. Selective Inhibition of Nuclear Export With Oral Selinexor for Treatment of Relapsed or Refractory Multiple Myeloma

Author

Vogl, Dan T, Dingli, David, Cornell, Robert Frank, Huff, Carol Ann, Jagannath, Sundar, Bhutani, Divaya, Zonder, Jeffrey, Baz, Rachid, Nooka, Ajay, Richter, Joshua, Cole, Craig, Vij, Ravi, Jakubowiak, Andrzej, Abonour, Rafat, Schiller, Gary, Parker, Terri L, Costa, Luciano J, Kaminetzky, David, Hoffman, James E, Yee, Andrew J, Chari, Ajai, Siegel, David, Fonseca, Rafael, Van Wier, Scott, Ahmann, Gregory, Lopez, Ilsel, Kauffman, Michael, Shacham, Sharon, Saint-Martin, Jean-Richard, Picklesimer, Carla D, Choe-Juliak, Cassandra, and Stewart, A Keith

Subjects
Hematology, Cancer, Clinical Research, Clinical Trials and Supportive Activities, Rare Diseases, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Active Transport, Cell Nucleus, Administration, Oral, Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Dexamethasone, Dose-Response Relationship, Drug, Female, Humans, Hydrazines, Karyopherins, Male, Middle Aged, Multiple Myeloma, Progression-Free Survival, Receptors, Cytoplasmic and Nuclear, Triazoles, Clinical Sciences, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

Purpose Selinexor, a first-in-class, oral, selective exportin 1 (XPO1) inhibitor, induces apoptosis in cancer cells through nuclear retention of tumor suppressor proteins and the glucocorticoid receptor, along with inhibition of translation of oncoprotein mRNAs. We studied selinexor in combination with low-dose dexamethasone in patients with multiple myeloma refractory to the most active available agents. Patients and Methods This phase II trial evaluated selinexor 80 mg and dexamethasone 20 mg, both orally and twice weekly, in patients with myeloma refractory to bortezomib, carfilzomib, lenalidomide, and pomalidomide (quad-refractory disease), with a subset also refractory to an anti-CD38 antibody (penta-refractory disease). The primary end point was overall response rate (ORR). Results Of 79 patients, 48 had quad-refractory and 31 had penta-refractory myeloma. Patients had received a median of seven prior regimens. The ORR was 21% and was similar for patients with quad-refractory (21%) and penta-refractory (20%) disease. Among patients with high-risk cytogenetics, including t(4;14), t(14;16), and del(17p), the ORR was 35% (six of 17 patients). The median duration of response was 5 months, and 65% of responding patients were alive at 12 months. The most common grade ≥ 3 adverse events were thrombocytopenia (59%), anemia (28%), neutropenia (23%), hyponatremia (22%), leukopenia (15%), and fatigue (15%). Dose interruptions for adverse events occurred in 41 patients (52%), dose reductions occurred in 29 patients (37%), and treatment discontinuation occurred in 14 patients (18%). Conclusion The combination of selinexor and dexamethasone has an ORR of 21% in patients with heavily pretreated, refractory myeloma with limited therapeutic options.

Published
2018

15. Effect of talquetamab on responses in patients with relapsed and refractory multiple myeloma with prior exposure to T-cell directed therapies.

Author

Graeter, Allison, primary, Castaneda Puglianini, Omar Alexis, additional, Hansen, Doris K., additional, Vazquez-Martinez, Mariola A., additional, Blue, Brandon Jamaal, additional, Khadka, Sushmita, additional, Liu, Hien, additional, Ochoa-Bayona, Jose L., additional, Freeman, Ciara L., additional, Locke, Frederick L, additional, Nishihori, Taiga, additional, Shain, Kenneth H., additional, Baz, Rachid C., additional, Alsina, Melissa, additional, and Grajales-Cruz, Ariel Felipe, additional

Published
2024
Full Text
View/download PDF

16. Metabolomic signatures of carfilzomib‐related cardiotoxicity in patients with multiple myeloma

Author

Shabnaz, Samia, primary, Nguyen, Trang N., additional, Williams, Roy, additional, Rubinstein, Samuel M., additional, Garrett, Timothy J., additional, Tantawy, Marwa, additional, Fradley, Michael G., additional, Alomar, Mohammed E., additional, Shain, Kenneth H., additional, Baz, Rachid C., additional, Lenihan, Daniel, additional, Cornell, Robert F., additional, Lu, Qing, additional, and Gong, Yan, additional

Published
2024
Full Text
View/download PDF

17. Simple Score of Albumin and CRP Predicts High-Grade Toxicity in Patients with Multiple Myeloma Receiving CAR-T Therapy

Author

Akhtar, Othman S., Modi, Karnav, Kim, Jongphil, Skelson, Lawrence, Smith, Eric, Al-Jumayli, Mohammed A., Extermann, Martine, De Avila, Gabriel, Parker, Nathan, Castaneda Puglianini, Omar, Grajales Cruz, Ariel, Baz, Rachid, Blue, Brandon, Shain, Kenneth, Alsina, Melissa, Liu, Hien, Nishihori, Taiga, Jain, Michael D., Locke, Frederick L., Hansen, Doris K., and Freeman, Ciara L.

Published
2024
Full Text
View/download PDF

18. Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group

Author

Moreau, Philippe, Kumar, Shaji K, San Miguel, Jesús, Davies, Faith, Zamagni, Elena, Bahlis, Nizar, Ludwig, Heinz, Mikhael, Joseph, Terpos, Evangelos, Schjesvold, Fredrik, Martin, Thomas, Yong, Kwee, Durie, Brian G M, Facon, Thierry, Jurczyszyn, Artur, Sidana, Surbhi, Raje, Noopur, van de Donk, Niels, Lonial, Sagar, Cavo, Michele, Kristinsson, Sigurdur Y, Lentzsch, Suzanne, Hajek, Roman, Anderson, Kenneth C, João, Cristina, Einsele, Hermann, Sonneveld, Pieter, Engelhardt, Monika, Fonseca, Rafael, Vangsted, Annette, Weisel, Katja, Baz, Rachid, Hungria, Vania, Berdeja, Jesus G, Leal da Costa, Fernando, Maiolino, Angelo, Waage, Anders, Vesole, David H, Ocio, Enrique M, Quach, Hang, Driessen, Christoph, Bladé, Joan, Leleu, Xavier, Riva, Eloisa, Bergsagel, Peter Leif, Hou, Jian, Chng, Wee Joo, Mellqvist, Ulf-Henrik, Dytfeld, Dominik, Harousseau, Jean-Luc, Goldschmidt, Hartmut, Laubach, Jacob, Munshi, Nikhil C, Gay, Francesca, Beksac, Meral, Costa, Luciano J, Kaiser, Martin, Hari, Parameswaran, Boccadoro, Mario, Usmani, Saad Z, Zweegman, Sonja, Holstein, Sarah, Sezer, Orhan, Harrison, Simon, Nahi, Hareth, Cook, Gordon, Mateos, Maria-Victoria, Rajkumar, S Vincent, Dimopoulos, Meletios A, and Richardson, Paul G

Published
2021
Full Text
View/download PDF

19. Linvoseltamab for Treatment of Relapsed/Refractory Multiple Myeloma.

Author

Bumma, Naresh, Richter, Joshua, Jagannath, Sundar, Lee, Hans C., Hoffman, James E., Suvannasankha, Attaya, Zonder, Jeffrey A., Shah, Mansi R., Lentzsch, Suzanne, Baz, Rachid, Maly, Joseph J., Namburi, Swathi, Pianko, Matthew J., Ye, Jing Christine, Wu, Ka Lung, Silbermann, Rebecca, Min, Chang-Ki, Vekemans, Marie-Christiane, Munder, Markus, and Byun, Ja Min

Published
2024
Full Text
View/download PDF

21. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study

Author

Lonial, Sagar, Lee, Hans C, Badros, Ashraf, Trudel, Suzanne, Nooka, Ajay K, Chari, Ajai, Abdallah, Al-Ola, Callander, Natalie, Lendvai, Nikoletta, Sborov, Douglas, Suvannasankha, Attaya, Weisel, Katja, Karlin, Lionel, Libby, Edward, Arnulf, Bertrand, Facon, Thierry, Hulin, Cyrille, Kortüm, K Martin, Rodríguez-Otero, Paula, Usmani, Saad Z, Hari, Parameswaran, Baz, Rachid, Quach, Hang, Moreau, Philippe, Voorhees, Peter M, Gupta, Ira, Hoos, Axel, Zhi, Eric, Baron, January, Piontek, Trisha, Lewis, Eric, Jewell, Roxanne C, Dettman, Elisha J, Popat, Rakesh, Esposti, Simona Degli, Opalinska, Joanna, Richardson, Paul, and Cohen, Adam D

Published
2020
Full Text
View/download PDF

22. Idecabtagene Vicleucel (ide-cel) Versus Standard Regimens (SRs) in Triple-Class–Exposed (TCE) Relapsed and Refractory Multiple Myeloma (RRMM): KarMMa-3 Subanalysis of Black Patients (pts)

Author

Patel, Krina K., primary, Rodríguez-Otero, Paula, additional, Nooka, Ajay K., additional, Callander, Natalie S., additional, Solomon, Scott R., additional, Baz, Rachid, additional, Sborov, Douglas W., additional, Gergis, Usama, additional, Badros, Ashraf Z., additional, Giralt, Sergio A., additional, Pearse, Roger, additional, Abonour, Rafat, additional, Siegel, David S., additional, Larson, Sarah M., additional, Munshi, Nikhil C., additional, Truppel-Hartmann, Anna, additional, Bhatnagar, Rashmi, additional, Wu, Fan, additional, Piasecki, Julia, additional, Felten, Jasper, additional, Caia, Andrea, additional, Cook, Mark, additional, Mckiver, Mihaela Popa, additional, Jagannath, Sundar, additional, and Ailawadhi, Sikander, additional

Published
2024
Full Text
View/download PDF

23. Evaluation of Outpatient Administration of Ciltacabtagene Autoleucel in Relapsed/Refractory Multiple Myeloma: Single Center Experience

Author

Waqar, Syed Hamza Bin, primary, Hansen, Doris K, additional, Freeman, Ciara Louise, additional, De Avila, Gabe, additional, Harvey, Kristy, additional, Grajales, Ariel, additional, Blue, Brandon, additional, Liu, Hien, additional, Baz, Rachid, additional, Alsina, Melissa, additional, Shain, Kenneth, additional, Jain, Michael D., additional, Locke, Frederick L., additional, Castaneda, Omar, additional, and Nishihori, Taiga, additional

Published
2024
Full Text
View/download PDF

24. Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology

Author

Kumar, Shaji K., primary, Callander, Natalie S., additional, Adekola, Kehinde, additional, Anderson, Larry D., additional, Baljevic, Muhamed, additional, Baz, Rachid, additional, Campagnaro, Erica, additional, Castillo, Jorge J., additional, Costello, Caitlin, additional, D’Angelo, Christopher, additional, Derman, Benjamin, additional, Devarakonda, Srinivas, additional, Elsedawy, Noura, additional, Garfall, Alfred, additional, Godby, Kelly, additional, Hillengass, Jens, additional, Holmberg, Leona, additional, Htut, Myo, additional, Huff, Carol Ann, additional, Hultcrantz, Malin, additional, Kang, Yubin, additional, Larson, Sarah, additional, Lee, Hans, additional, Liedtke, Michaela, additional, Martin, Thomas, additional, Omel, James, additional, Robinson, Timothy, additional, Rosenberg, Aaron, additional, Sborov, Douglas, additional, Schroeder, Mark A., additional, Sherbenou, Daniel, additional, Suvannasankha, Attaya, additional, Valent, Jason, additional, Varshavsky-Yanovsky, Asya Nina, additional, Snedeker, Jenna, additional, and Kumar, Rashmi, additional

Published
2024
Full Text
View/download PDF

25. Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial

Author

Lim, Andrew, Grigoriadis, George, Walker, Trish, Nicol, Andrew, LeBlanc, Richard, Reece, Donna, Elemary, Mohamed, Boudreault Pedneault, Jean Samuel, Karlin, Lionel, Facon, Thierry, Attal, Michel, Weisel, Katja, Engelhardt, Monika, Mackensen, Andreas, Quinn, John, Avivi, Irit, Cohen, Amos, Magen-Nativ, Hila, Benyamini, Noam, Cavo, Michele, Larocca, Alessandra, Takezako, Naoki, Suzuki, Kenshi, Kosugi, Hiroshi, Matsumoto, Morio, Iida, Shinsuke, Ishikawa, Takayuki, Kondo, Yukio, Sunami, Kazutaka, Ando, Kiyoshi, Teshima, Takanori, Chou, Takaaki, Iwasaki, Hiromi, Miki, Hirokazu, Matsumura, Itaru, Onishi, Yasushi, Izutsu, Koji, Kizaki, Masahiro, George, Anupkumar, Blacklock, Hillary, Simpson, David, Schjesvold, Fredrik, Waage, Anders, Samoilova, Olga, Nikitin, Evgeniy, Chagorova, Tatiana, McDonald, Andrew, Patel, Moosa, Oriol Rocafiguera, Albert, San Miguel Izquierdo, Jesus, Mateos, Maria, Streetly, Matthew, Forsyth, Peter, Jackson, Graham, Jenkins, Stephen, Rifkin, Robert, Yimer, Habte, McCroskey, Robert, Martincic, Danko, Tarantolo, Stefano, Larson, Sarah, Faroun, Yacoub, Vaughn, Jennifer, Baz, Rachid, Saylors, Gene, Neppalli, Amarendra, Raptis, Anastasios, Fung, Henry, Janosky, Maxwell, Stevens, Don, Coleman, Morton, Costa, Dennis, Cross, Scott, Fanning, Suzanne, Berges, Daniel Farray, Harris, Thomas, Zackon, Ira, Atanackovic, Djordje, Lee, Kelvin, Oliff, Ira, Lee, Wes, Bensinger, William, Lutzky, Jose, Baron, Ari, Hayek, Fadi, Kirschner, Eli, Bharany, Neeraj, Overton, Lindsay, Mannem, Siva, Harroff, Allyson, Jain, Sharad, Roque, Tammy, McIntyre, Kristi, Yasencha, Christopher K, Houck, William, Usmani, Saad Zafar, Oriol, Albert, Rifkin, Robert M, Yimer, Habte Aragaw, McCroskey, Robert Donald, Lim, Andrew Boon Ming, Jagannath, Sundar, Lonial, Sagar, Ghori, Razi Uddin, Farooqui, Mohammed Z H, Marinello, Patricia, and San-Miguel, Jesus

Published
2019
Full Text
View/download PDF

26. Multiple Myeloma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology

Author

Kumar, Shaji K., primary, Callander, Natalie S., additional, Adekola, Kehinde, additional, Anderson, Larry D., additional, Baljevic, Muhamed, additional, Baz, Rachid, additional, Campagnaro, Erica, additional, Castillo, Jorge J., additional, Costello, Caitlin, additional, D’Angelo, Christopher, additional, Devarakonda, Srinivas, additional, Elsedawy, Noura, additional, Garfall, Alfred, additional, Godby, Kelly, additional, Hillengass, Jens, additional, Holmberg, Leona, additional, Htut, Myo, additional, Huff, Carol Ann, additional, Hultcrantz, Malin, additional, Kang, Yubin, additional, Larson, Sarah, additional, Lee, Hans C., additional, Liedtke, Michaela, additional, Martin, Thomas, additional, Omel, James, additional, Robinson, Timothy, additional, Rosenberg, Aaron, additional, Sborov, Douglas, additional, Schroeder, Mark A., additional, Sherbenou, Daniel, additional, Suvannasankha, Attaya, additional, Valent, Jason, additional, Varshavsky-Yanovsky, Asya Nina, additional, Kumar, Rashmi, additional, and Snedeker, Jenna, additional

Published
2023
Full Text
View/download PDF

27. Supplementary Figure S5 from Survivin Dendritic Cell Vaccine Safely Induces Immune Responses and Is Associated with Durable Disease Control after Autologous Transplant in Patients with Myeloma

Author

Freeman, Ciara L., primary, Atkins, Reginald, primary, Varadarajan, Indumathy, primary, Menges, Meghan, primary, Edelman, Jeffrey, primary, Baz, Rachid, primary, Brayer, Jason, primary, Castaneda Puglianini, Omar, primary, Ochoa-Bayona, Jose Leonel, primary, Nishihori, Taiga, primary, Shain, Kenneth H., primary, Shah, Bijal, primary, Chen, Dung Tsa, primary, Kelley, Linda, primary, Coppola, Domenico, primary, Alsina, Melissa, primary, Antonia, Scott, primary, Anasetti, Claudio, primary, and Locke, Frederick L., primary

Published
2023
Full Text
View/download PDF

28. Supplementary Table S3 from Survivin Dendritic Cell Vaccine Safely Induces Immune Responses and Is Associated with Durable Disease Control after Autologous Transplant in Patients with Myeloma

Author

Freeman, Ciara L., primary, Atkins, Reginald, primary, Varadarajan, Indumathy, primary, Menges, Meghan, primary, Edelman, Jeffrey, primary, Baz, Rachid, primary, Brayer, Jason, primary, Castaneda Puglianini, Omar, primary, Ochoa-Bayona, Jose Leonel, primary, Nishihori, Taiga, primary, Shain, Kenneth H., primary, Shah, Bijal, primary, Chen, Dung Tsa, primary, Kelley, Linda, primary, Coppola, Domenico, primary, Alsina, Melissa, primary, Antonia, Scott, primary, Anasetti, Claudio, primary, and Locke, Frederick L., primary

Published
2023
Full Text
View/download PDF

29. Data from Survivin Dendritic Cell Vaccine Safely Induces Immune Responses and Is Associated with Durable Disease Control after Autologous Transplant in Patients with Myeloma

Author

Freeman, Ciara L., primary, Atkins, Reginald, primary, Varadarajan, Indumathy, primary, Menges, Meghan, primary, Edelman, Jeffrey, primary, Baz, Rachid, primary, Brayer, Jason, primary, Castaneda Puglianini, Omar, primary, Ochoa-Bayona, Jose Leonel, primary, Nishihori, Taiga, primary, Shain, Kenneth H., primary, Shah, Bijal, primary, Chen, Dung Tsa, primary, Kelley, Linda, primary, Coppola, Domenico, primary, Alsina, Melissa, primary, Antonia, Scott, primary, Anasetti, Claudio, primary, and Locke, Frederick L., primary

Published
2023
Full Text
View/download PDF

32. A Phase II Trial of Bortezomib and Vorinostat in Mantle Cell Lymphoma and Diffuse Large B-cell Lymphoma

Author

Yazbeck, Victor, Shafer, Danielle, Perkins, Edward B., Coppola, Domenico, Sokol, Lubomir, Richards, Kristy L., Shea, Thomas, Ruan, Jia, Parekh, Samir, Strair, Roger, Flowers, Christopher, Morgan, David, Kmieciak, Maciej, Bose, Prithviraj, Kimball, Amy, Badros, Ashraf Z., Baz, Rachid, Lin, Hui-Yi, Zhao, Xiuhua, Reich, Richard R., Tombes, Mary Beth, Shrader, Ellen, Sankala, Heidi, Roberts, John D., Sullivan, Daniel, Grant, Steven, and Holkova, Beata

Published
2018
Full Text
View/download PDF

34. Patient-Reported Outcomes among Multiple Myeloma Patients Treated with Standard of Care Idecabtagene Vicleucel

Author

Oswald, Laura B., primary, Gudenkauf, Lisa M., additional, Li, Xiaoyin, additional, De Avila, Gabriel, additional, Peres, Lauren C., additional, Kirtane, Kedar, additional, Gonzalez, Brian D., additional, Hoogland, Aasha I., additional, Nguyen, Oanh, additional, Rodriguez, Yvelise, additional, Baz, Rachid C., additional, Shain, Kenneth H., additional, Alsina, Melissa, additional, Locke, Frederick L., additional, Freeman, Ciara, additional, Castaneda Puglianini, Omar, additional, Nishihori, Taiga, additional, Liu, Hien, additional, Blue, Brandon, additional, Grajales-Cruz, Ariel, additional, Jim, Heather S. L., additional, and Hansen, Doris K., additional

Published
2023
Full Text
View/download PDF

35. P-032 Ide-cel versus standard regimens in patients with triple-class–exposed (TCE) relapsed and refractory multiple myeloma (RRMM): a KarMMa-3 analysis in the modified intention to-treat (mITT) population

Author

Manier, Salomon, primary, Ailawadhi, Sikander, additional, Rodriguez-Otero, Paula, additional, Arnulf, Bertrand, additional, Patel, Krina, additional, Solomon, Scott, additional, Baz, Rachid, additional, Jagannath, Sundar, additional, Raje, Noopur, additional, Scheid, Christoph, additional, Mateos, Maria-Victoria, additional, Abdallah, Al-Ola, additional, Einsele, Hermann, additional, Giralt, Sergio, additional, Pabst, Thomas Mueller, additional, Perrot, Aurore, additional, Lin, Yi, additional, Truppel-Hartmann, Anna, additional, Bhatnagar, Rashmi, additional, Felten, Jasper, additional, Caia, Andrea, additional, Piasecki, Julia, additional, Cook, Mark, additional, and Moreau, Philippe, additional

Published
2023
Full Text
View/download PDF

36. MM-059 Incidence and Risk Factors Associated With Bleeding Following Anti-B-Cell Maturation Antigen (BCMA) Chimeric Antigen Receptor (CAR) T-Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)

Author

Mohammed, Turab, primary, Peres, Lauren, additional, Colinleitzinger, Christelle, additional, Puglianini, Omar Castaneda, additional, Oswald, Laura, additional, de Avila, Gabe, additional, Grajales-Cruz, Ariel, additional, Blue, Brandon, additional, Ochoa-Bayona, Jose, additional, Khimani, Farhad, additional, Faramand, Rawan, additional, Elmariah, Hany, additional, Lazaryan, Aleksandr, additional, Jain, Michael, additional, Liu, Hein, additional, Nishihori, Taiga, additional, Shain, Ken, additional, Baz, Rachid, additional, Alsina, Melissa, additional, Locke, Frederick, additional, Freeman, Ciara, additional, and Hansen, Doris, additional

Published
2023
Full Text
View/download PDF

37. P-040 Idecabtagene vicleucel (ide-cel) versus standard regimens in patients with triple-class-exposed (TCE) relapsed and refractory multiple myeloma (RRMM): a KarMMa-3 high-risk subgroup analysis

Author

Patel, Krina, primary, Rodriguez-Otero, Paula, additional, Manier, Salomon, additional, Baz, Rachid, additional, Raab, Marc, additional, Cavo, Michele, additional, Callander, Natalie, additional, Costa, Luciano, additional, Moreau, Philippe, additional, Solomon, Scott, additional, Chen, Christine, additional, Raje, Noopur, additional, Scheid, Christoph, additional, Delforge, Michel, additional, Larsen, Jeremy, additional, Pabst, Thomas Mueller, additional, Suzuki, Kenshi, additional, Truppel-Hartmann, Anna, additional, Yang, Zhihong, additional, Piasecki, Julia, additional, Felten, Jasper, additional, Caia, Andrea, additional, Cook, Mark, additional, Giralt, Sergio, additional, and Mateos, Maria-Victoria, additional

Published
2023
Full Text
View/download PDF

38. POSTER: MM-388 Idecabtagene Vicleucel (ide-cel) Versus Standard Regimens in Patients With Triple-Class–Exposed (TCE) Relapsed and Refractory Multiple Myeloma (RRMM): A KarMMa-3 Analysis in High-Risk Subgroups

Author

Patel, Krina, primary, Rodríguez-Otero, Paula, additional, Manier, Salomon, additional, Baz, Rachid, additional, Raab, Mark-Steffen, additional, Cavo, Michele, additional, Callander, Natalie, additional, Costa, Luciano J., additional, Moreau, Phillippe, additional, Solomon, Scott, additional, Chen, Christine, additional, Raje, Noopur, additional, Scheid, Christoph, additional, Delforge, Michel, additional, Larsen, Jeremy, additional, Pabst, Thomas, additional, Suzuki, Kenshi, additional, Truppel-Hartmann, Anna, additional, Yang, Zhihong, additional, Piasecki, Julia, additional, Felten, Jasper, additional, Caia, Andrea, additional, Cook, Mark, additional, Giralt, Sergio, additional, and Mateos, Maria-Victoria, additional

Published
2023
Full Text
View/download PDF

39. P-277 Venetoclax versus bortezomib, in combination with daratumumab and dexamethasone, in patients with t(11;14)-positive relapsed or refractory multiple myeloma

Author

Kaufman, Jonathan, primary, Quach, Hang, additional, Baz, Rachid, additional, Vangsted, Annette Juul, additional, Ho, Shir-Jing, additional, Abildgaard, Niels, additional, Laubach, Jacob, additional, Ribrag, Vincent, additional, Gibbs, Simon, additional, Medvedova, Eva, additional, Voorhees, Peter, additional, Jalaluddin, Muhammad, additional, Zeng, Jiewei, additional, Ross, Jeremy, additional, Wang, Xifeng, additional, Fleming, Leanne Lash, additional, Bueno, Orlando, additional, Luo, Yan, additional, and Bahlis, Nizar, additional

Published
2023
Full Text
View/download PDF

40. P-031 Idecabtagene vicleucel (ide-cel) vs standard regimens in patients with triple-class–exposed (TCE) relapsed and refractory multiple myeloma (RRMM): KarMMa-3 subgroup analysis by prior lines of therapy

Author

Manier, Salomon, primary, Rodriguez-Otero, Paula, additional, Mateos, Maria-Victoria, additional, Einsele, Hermann, additional, Bahlis, Nizar, additional, Munshi, Nikhil, additional, Ailawadhi, Sikander, additional, Arnulf, Bertrand, additional, Nooka, Ajay, additional, Vij, Ravi, additional, Abrahamsen, Ingerid Weum, additional, Broijl, Annemiek, additional, Jagannath, Sundar, additional, Benjamin, Reuben, additional, Gergis, Usama, additional, Sborov, Douglas, additional, Iida, Shinsuke, additional, Truppel-Hartmann, Anna, additional, Yang, Zhihong, additional, Bhatnagar, Rashmi, additional, Piasecki, Julia, additional, Felten, Jasper, additional, Caia, Andrea, additional, Cook, Mark, additional, and Baz, Rachid, additional

Published
2023
Full Text
View/download PDF

41. P-213 COVALENT-101: phase I study of BMF-219, a covalent menin inhibitor, in adult patients with AML, ALL (with KMT2A/ MLL1r, NPM1 mutations), DLBCL, MM, and CLL/SLL (NCT05153330)

Author

Rosenberg, Aaron, primary, Baljevic, Muhamed, additional, Amor, Adrian Alegre, additional, Barrientos, Jacqueline, additional, Bashey, Asad, additional, Baz, Rachid, additional, Burgues, Juan Bergua, additional, Delimpasi, Sosana, additional, Kastritis, Efstathios, additional, Latif, Tahir, additional, Lee, Lisa, additional, Mateos, Maria-Victoria, additional, Morillo, Daniel, additional, Montesinos, Pau, additional, Parrondo, Ricardo, additional, Schiller, Gary, additional, Curran, Emily, additional, Kishtagari, Ashwin, additional, Butler, Thomas, additional, Cacovean, Alex, additional, Follit, Courtney, additional, Mandap, Clarissa, additional, Morris, Steve, additional, and Khouri, Jack, additional

Published
2023
Full Text
View/download PDF

42. P-247 Efficacy and safety of linvoseltamab 200 mg in patients with relapsed/refractory multiple myeloma (RRMM): analysis of the LINKER-MM1 study

Author

Dhodapkar, Madhav, primary, Bumma, Naresh, additional, Richter, Joshua, additional, Lee, Hans, additional, Hoffman, James, additional, Suvannasankha, Attaya, additional, Lentzsch, Suzanne, additional, Shah, Mansi, additional, Zonder, Jeffrey, additional, Baz, Rachid, additional, Wu, Ka Lung, additional, Pianko, Matthew, additional, Silbermann, Rebecca, additional, Min, Chang-Ki, additional, Vekemans, Marie-Christiane Madeleine, additional, Munder, Markus, additional, Byun, Ja Min, additional, Lopez, Joaquín Martínez, additional, DeVeaux, Michelle, additional, Lorenc, Karen Rodriguez, additional, Kroog, Glenn, additional, Houvras, Yariv, additional, and Jagannath, Sundar, additional

Published
2023
Full Text
View/download PDF

43. MM-388 Idecabtagene Vicleucel (ide-cel) Versus Standard Regimens in Patients With Triple-Class–Exposed (TCE) Relapsed and Refractory Multiple Myeloma (RRMM): A KarMMa-3 Analysis in High-Risk Subgroups

Author

Patel, Krina, primary, Rodríguez-Otero, Paula, additional, Manier, Salomon, additional, Baz, Rachid, additional, Raab, Mark-Steffen, additional, Cavo, Michele, additional, Callander, Natalie, additional, Costa, Luciano J., additional, Moreau, Phillippe, additional, Solomon, Scott, additional, Chen, Christine, additional, Raje, Noopur, additional, Scheid, Christoph, additional, Delforge, Michel, additional, Larsen, Jeremy, additional, Pabst, Thomas, additional, Suzuki, Kenshi, additional, Truppel-Hartmann, Anna, additional, Yang, Zhihong, additional, Piasecki, Julia, additional, Felten, Jasper, additional, Caia, Andrea, additional, Cook, Mark, additional, Giralt, Sergio, additional, and Mateos, Maria-Victoria, additional

Published
2023
Full Text
View/download PDF

44. Safety and efficacy of anti-BCMA CAR-T cell therapy in older adults with multiple myeloma: A systematic review and meta-analysis

Author

Akhtar, Othman Salim, primary, Sheeba, Ba Aqeel, additional, Azad, Farhan, additional, Alessi, Lauren, additional, Hansen, Doris, additional, Alsina, Melissa, additional, Baz, Rachid, additional, Shain, Kenneth, additional, Grajales Cruz, Ariel, additional, Castaneda Puglianini, Omar, additional, Liu, Hien, additional, Blue, Brandon, additional, Nishihori, Taiga, additional, Al Jumayli, Mohammed, additional, Extermann, Martine, additional, Locke, Frederick L., additional, Mhaskar, Rahul, additional, and Freeman, Ciara Louise, additional

Published
2023
Full Text
View/download PDF

45. POSTER: MM-059 Incidence and Risk Factors Associated With Bleeding Following Anti-B-Cell Maturation Antigen (BCMA) Chimeric Antigen Receptor (CAR) T-Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)

Author

Mohammed, Turab, primary, Peres, Lauren, additional, Colinleitzinger, Christelle, additional, Puglianini, Omar Castaneda, additional, Oswald, Laura, additional, de Avila, Gabe, additional, Grajales-Cruz, Ariel, additional, Blue, Brandon, additional, Ochoa-Bayona, Jose, additional, Khimani, Farhad, additional, Faramand, Rawan, additional, Elmariah, Hany, additional, Lazaryan, Aleksandr, additional, Jain, Michael, additional, Liu, Hein, additional, Nishihori, Taiga, additional, Shain, Ken, additional, Baz, Rachid, additional, Alsina, Melissa, additional, Locke, Frederick, additional, Freeman, Ciara, additional, and Hansen, Doris, additional

Published
2023
Full Text
View/download PDF

46. P866: IDECABTAGENE VICLEUCEL (IDE-CEL) VS STANDARD REGIMENS IN PATIENTS WITH TRIPLE-CLASS–EXPOSED (TCE) RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM): KARMMA-3 SUBGROUP ANALYSIS BY PRIOR LINES OF THERAPY

Author

Manier, Salomon, primary, Rodríguez-Otero, Paula, additional, Mateos, Maria-Victoria, additional, Einsele, Hermann, additional, Bahlis, Nizar J, additional, Munshi, Nikhil, additional, Ailawadhi, Sikander, additional, Arnulf, Bertrand, additional, Nooka, Ajay, additional, Vij, Ravi, additional, Weum Abrahamsen, Ingerid, additional, Broijl, Annemiek, additional, Jagannath, Sundar, additional, Benjamin, Reuben, additional, Gergis, Usama, additional, Sborov, Douglas W., additional, Iida, Shinsuke, additional, Truppel-Hartmann, Anna, additional, Yang, Zhihong, additional, Piasecki, Julia, additional, Felten, Jasper, additional, Caia, Andrea, additional, Cook, Mark, additional, and Baz, Rachid, additional

Published
2023
Full Text
View/download PDF

48. S195: IDECABTAGENE VICLEUCEL (IDE-CEL) VS STANDARD REGIMENS IN PATIENTS WITH TRIPLE-CLASS–EXPOSED (TCE) RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM): A KARMMA-3 ANALYSIS IN HIGH-RISK SUBGROUPS

Author

Patel, Krina, primary, Rodríguez-Otero, Paula, additional, Manier, Salomon, additional, Baz, Rachid, additional, Raab, Marc S., additional, Cavo, Michele, additional, Callander, Natalie, additional, Costa, Luciano, additional, Moreau, Philippe, additional, Solomon, Scott, additional, Chen, Christine, additional, Raje, Noopur, additional, Scheid, Christof, additional, Delforge, Michel, additional, Larsen, Jeremy, additional, Pabst, Thomas, additional, Suzuki, Kenshi, additional, Truppel-Hartmann, Anna, additional, Yang, Zhihong, additional, Piasecki, Julia, additional, Felten, Jasper, additional, Caia, Andrea, additional, Cook, Mark, additional, Giralt, Sergio, additional, and Mateos, Maria-Victoria, additional

Published
2023
Full Text
View/download PDF

49. PB2092: INCIDENCE AND RISK FACTORS ASSOCIATED WITH BLEEDING FOLLOWING ANTI-B CELL MATURATION ANTIGEN CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

Author

Mohammed, Turab, primary, Shahzad, Moazzam, additional, Peres, Lauren, additional, Khadka, Sushmita, additional, Colinleitzinger, Christelle, additional, Babu, Abida, additional, Doyle, William, additional, Puglianini, Omar Castaneda, additional, Oswald, Laura, additional, De Avila, Gabe, additional, Grajales-Cruz, Ariel, additional, Blue, Brandon, additional, Ochoa-Bayona, Jose, additional, Smith, Eric, additional, Corallo, Salvatore, additional, Khimani4, Farhad, additional, Faramand, Rawan, additional, Elmariah, Hany, additional, Lazaryan, Aleksandr, additional, Jain, Michael, additional, Liu, Hien, additional, Nishihori, Taiga, additional, Shain, Ken, additional, Baz, Rachid, additional, Alsina, Melissa, additional, Locke, Frederick, additional, Freeman, Ciara, additional, and Hansen, Doris, additional

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results